英文翻译成中文： The amendments specify that it is not an infringement to make, use, and sell a patented invention if it is done solely to develop and submit information to Canadian or other government authorities that regulate the manufacture, use, or sale of patented inventions. Thus, clinical trials of a patented medicine will be permitted in the absence of a license from the patent owner. Also, testing of products other than medicines to submit information to the government is not an infringement. Notices of compliance or other permits to manufacture, use, or sell a patented invention issued to persons other than the patent owner may not take effect immediately. The earliest effective date of these types of permits will be set out in regulations. Presumably, the effective date of a notice of compliance issued to persons other than the patent owner will coincide with the date of expiry of the patent on the medicine or the date that the patent owner ceased to be entitled to the benefit of the patent. If there is any inconsistency between these regulations and any other federal legislation, such as the regulations under the Food and Drugs Act, as amended, these Patent Act regulations will prevail. The amendments also state that a person can manufacture and store patented inventions intended for sale after the expiry of a patent even while the patent is in force. The manufacture and storage must be carried out during a period to be prescribed by regulation. The amendments described above have received Royal Assent, but have not yet been proclaimed in force. The government is drafting regulations relating to these amendments, and the amendments will likely be proclaimed once the regulations are in place.